34 / 1983
ESTRO: Evidence-based Radiation Oncology
Personalised medicine
• PFS2/PFS1 >1.3 in 33% (63/193)
• 7%
of the successfully screened
patients benefited from this approach
Massard Cancer Discov; 2017
|
|
34 / 1983
ESTRO: Evidence-based Radiation Oncology
Personalised medicine
• PFS2/PFS1 >1.3 in 33% (63/193)
• 7%
of the successfully screened
patients benefited from this approach
Massard Cancer Discov; 2017